Title:
コレステロール輸送の調節のための化合物
Document Type and Number:
Japanese Patent JP2006515274
Kind Code:
A
Abstract:
Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically downregulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in rat adrenal membranes and other non-placental steroidogenic tissues from animals treated with estrogen, but not in other non-placental non-steroidogenic tissues, including lung, liver, and skin. Examples further demonstrate the uptake of fluorescently labeled HDL into the liver cells of animal, which does not occur when the animals are treated with estrogen. Examples also demonstrate the in vivo effects of SR-BI expression on HDL metabolism, in mice transiently overexpressing hepatic SR-BI following recombinant adenovirus infection. Overexpression of the SR-BI in the hepatic tissue caused a dramatic decrease in cholesterol blood levels. These results demonstrate that modulation of SR-BI levels, either directly or indirectly, can be used to modulate levels of cholesterol in the blood.
More Like This:
| WO/1994/007897 | SYNTHESES OF D-CHIRO-3-INOSOSE AND (+)-D-CHIRO-INOSITOL |
| JPH06321829 | ALPHA,ALPHA-DIMETHYLCYCLOHEXANECARBINOL DERIVATIVE OR ITS SALT |
| WO/1996/004229 | THE PREPARATION OF ORGANIC COMPOUNDS |
Inventors:
Kneeland, Thomas Jay. F.
Krieger, Monty
Kirkhausen, Thomas
Krieger, Monty
Kirkhausen, Thomas
Application Number:
JP2004543548A
Publication Date:
May 25, 2006
Filing Date:
October 08, 2003
Export Citation:
Assignee:
Massachusetts Institute of Technology
The CB R Institute for Biomedical Research, Incorporated
The CB R Institute for Biomedical Research, Incorporated
International Classes:
C07C49/497; A61K31/145; A61K31/166; A61K31/175; A61K31/192; A61K31/255; A61K31/337; A61K31/341; A61K31/343; A61K31/36; A61K31/381; A61K31/39; A61K31/4015; A61K31/402; A61K31/4025; A61K31/4035; A61K31/4045; A61K31/415; A61K31/4184; A61K31/422; A61K31/423; A61K31/4245; A61K31/426; A61K31/428; A61K31/433; A61K31/4355; A61K31/437; A61K31/4375; A61K31/439; A61K31/4409; A61K31/443; A61K31/4436; A61K31/4453; A61K31/451; A61K31/454; A61K31/4709; A61K31/472; A61K31/473; A61K31/496; A61K31/502; A61K31/519; A61K31/53; A61K31/536; A61K31/5377; A61K31/538; A61K31/5415; A61K31/554; A61K31/56; A61K38/00; A61K45/00; A61P3/06; A61P9/10; A61P15/18; C07C69/157; C07C211/50; C07C211/53; C07C215/26; C07C219/22; C07C233/07; C07C233/15; C07C233/76; C07C235/24; C07C243/38; C07C251/86; C07C251/88; C07C271/38; C07C271/58; C07C275/28; C07C275/34; C07C337/06; C07D205/08; C07D207/16; C07D207/27; C07D207/335; C07D207/416; C07D209/08; C07D209/12; C07D209/16; C07D209/40; C07D209/42; C07D209/44; C07D209/48; C07D209/86; C07D209/88; C07D211/52; C07D213/79; C07D215/28; C07D217/24; C07D221/08; C07D221/18; C07D223/22; C07D231/06; C07D231/16; C07D231/38; C07D233/42; C07D235/14; C07D235/22; C07D239/52; C07D251/18; C07D251/22; C07D251/70; C07D261/14; C07D263/56; C07D265/02; C07D265/36; C07D271/06; C07D277/20; C07D277/32; C07D277/36; C07D277/42; C07D277/48; C07D277/64; C07D277/66; C07D277/68; C07D277/74; C07D277/82; C07D279/16; C07D285/08; C07D295/10; C07D295/12; C07D295/20; C07D307/52; C07D307/73; C07D307/79; C07D317/28; C07D317/32; C07D319/18; C07D327/00; C07D333/22; C07D333/38; C07D333/68; C07D401/04; C07D401/12; C07D403/10; C07D405/04; C07D405/12; C07D409/14; C07D413/04; C07D413/06; C07D417/04; C07D417/06; C07D417/14; C07D453/02; C07D471/04; C07D487/04; C07D491/048; C07D495/04; C07D498/04; G01N33/15; G01N33/50; G01N33/53; G01N33/543; A61B
Attorney, Agent or Firm:
Hidesaku Yamamoto
Takaaki Yasumura
Natsuki Morishita
Takaaki Yasumura
Natsuki Morishita